Elin Haf Davies

Celebrating two years of using wearables and specific mobile apps to deliver patient monitoring outside of the hospital. Reflection from Founder & CEO I couldn’t be prouder of what we have achieved as a team at aparito over the last two years. In partnership with many great individuals and organisations, we have initiated five studies, in four different diseases across three countries. Through our work to date, I am more convinced than ever that our tech solution will go a long way towards improving the conduct of clinical trials and the effectiveness of managing routine care for paediatric patients and people living with rare diseases in particular. As we approach Rare Disease Day on the 28th of February, we look forward to continuing our work in the rare disease community and to collaborating further in order to make a positive impact to patients and their families.  With sincere thanks to all that have helped us so far - this is very much a collaborative effort. Warm Wishes, Elin  Our Studies 2016 In partnership with National Tay-Sachs & Allied Diseases Association, aparito is being used at the National Institutes of Health (NIH), in America to investigate the natural history of Gangliosidoses (GM1, GM2). This investigation started in August 2016. Newcastle Upon Tyne Hospitals are using aparito to monitor patients with Juvenile Idiopathic Arthritis between hospital visits in a POC study. This began in November 2016. In partnership with Niemann-Pick UK and International Niemann Pick Disease Alliance, aparito has been contracted by Actelion Pharmaceuticals to monitor patients with Niemann-Pick Type C (NPC). This study began in February 2016 at Great Ormond Street Hospital and later at Central Manchester University Hospitals NHS Foundation Trust. The Gaucher Association UK collaborated with aparito to develop a disease specific app for patients with neuronopathic Gaucher Disease to report their own experience of their condition. This was funded by Genzyme and Shire and began in June 2016 at Central Manchester University Hospitals NHS Foundation Trust. The Lysosomal Storage Disorder Society collaborated with aparito to investigate remote monitoring of participants with Gaucher disease across India. This user testing spanned a month from January 2016 and will initiate again February 2017. Our Awards 2016 aparito was named by Nesta as 1 of the 50 most radical-thinking organizations solving problems in the health system to improve the lives of individuals in the UK and beyond. As Mentioned in: The Guardian, "More of the Best New Radicals 2016"   aparito joined Velocity Health as a one of its 2016 start-ups dedicated to developing technologies that support individuals struggling with chronic illnesses. aparito was identified as a high-impact, high-potential start-up by MassChallenge UK, a start-up friendly accelerator focusing on improvements to the health of society. Welcoming to the team Dr. Ian Radford Executive Director, Software and Analytics, May 2016 Ian has been working in software development for 20 years following on from academic research in the areas of Machine Learning and Artificial Intelligence. Ian brings a culture of rigour and professionalism, along with modern lean methodologies.  By automating deployment and testing to the maximum degree we will streamline our development pipeline to maximise efficiency, releasing valuable resources to allow ground breaking use of Machine Learning with wearable technology, whilst at the same time providing a simple, clean and intuitive user experience for our clients. Chris Tyson CTO, March 2016 Chris comes with a wealth of experience in the Pharmaceutical sector focussing on the design and delivery of IT projects for Regulatory, Drug Safety, Clinical Development and Supply Chain clients including Astellas, AstraZeneca, GSK and Cancer Research UK. Chris comes from a software development background and holds an MBA from Manchester Business School.  Chris will lead the transformation of the current aparito technology stack to meet growing customer requirements and deliver full regulatory compliance under Computer System Validation. Learn more about aparito Podcast via Share Impact - 21 January 2017 aparito explained by Founder & CEO, Dr. Elin Haf Davies - 2 April 2015 Thank you for your continued support of the aparito mission.